Pharmaceutical News

RSS

Treprostinil drug reduces breathlessness in PAH patients, says study

Patients with a rare, deadly disease that mostly affects young women felt a dramatic reduction in breathlessness using an approved drug, according to study results published online today in The Journal of Heart and Lung Transplantation.

18 Dec 2009

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.

18 Dec 2009

BDI Pharma introduces SecuriVAX for online ordering of vaccines

BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced today the introduction of SecuriVAX(SM) (www.securivax.com), an online supply solution providing the healthcare community a one-stop source for a wide variety of vaccines.

18 Dec 2009

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.

18 Dec 2009

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Unigene Laboratories, Inc. (http://www.unigene.com) announced today that it has selected a lead peptide compound, designated UGP281, from its obesity program for development.

18 Dec 2009

Antidepressants may play a key role in improving adolescents’ mental health

Suicidal adolescents who were prescribed an antidepressant medication during inpatient psychiatric hospital treatment were 85 percent less likely than others to be readmitted within a month after discharge, a new study found.

18 Dec 2009

Duane Reade offers H1N1 immunization vaccines for New York residents

Duane Reade, the largest drug store chain in New York City, today announced plans for its H1N1 immunization program as part of the Company's commitment to meet the health and wellness needs of New Yorkers and to be a destination for their flu related needs.

18 Dec 2009

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

18 Dec 2009

Covidien signs definitive agreement to sell U.S. radiopharmacies to Triad Isotopes

Covidien, a leading global provider of healthcare products, today announced a definitive agreement to sell its radiopharmacies in the United States to Triad Isotopes, Inc. of Orlando, Florida. Triad operates a network of 26 nuclear radiopharmacies and six cyclotron facilities in the southeast United States. Financial terms of the transaction were not disclosed.

18 Dec 2009

Switching between A-rated anti-epileptic drug formulations does not increase seizure risk

Express Scripts, Inc., one of the largest pharmacy benefit management companies in North America, announced today results of a study that examined the association of seizure risk among epilepsy patients after switching between A-rated anti-epileptic drug formulations. The study found no evidence that switching between A-rated anti-epileptic drugs, including brand to generic substitution, was associated with increased emergency room visits or hospitalizations for epilepsy.

17 Dec 2009

EPA approves BASF's Aseptrol S10 - Tab for H1N1 sanitization operations

BASF today announced that the Environmental Protection Agency (EPA) has approved the use of Aseptrol® S10 - Tab in H1N1 sanitization operations in institutional and industrial facilities, such as, schools, hospitals, government buildings, retail and restaurants, and recreational facilities. Aseptrol S10 - Tab is based on Chlorine dioxide (CIO2) release technology.

17 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

Labopharm commences regulatory approval process in Europe for its twice-daily tramadol-acetaminophen

Labopharm Inc. today announced it has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under the Decentralized Procedure (DCP). The DCP provides an efficient mechanism that allows a company to simultaneously pursue regulatory approval for a medicinal product in multiple jurisdictions in Europe.

17 Dec 2009

Prophylactic misuse of NSAIDs cause more harm than good

Athletes' superstitions and rituals can help them get psyched up for contests, but when these rituals involve non-steroidal anti-inflammatory drugs (NSAIDs), which many athletes gobble down before and during events, they could be causing more harm than good.

17 Dec 2009

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by Swedish scientists at Uppsala University, is published in the December issue of the journal Vaccine.

17 Dec 2009

Three H1N1 influenza vaccination clinics scheduled to offer vaccines free of charge

2010 is just over two weeks away. Make a New Year's resolution for you and your family members and start the new year out right by getting your H1N1 influenza shot at one of the available clinics in southeast Michigan.

17 Dec 2009

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced that they have entered an agreement to develop, market and distribute LAS100977 in the United States.

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

ODAC to review Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).

17 Dec 2009

ODAC to conduct public advisory meeting to review ChemGenex Pharmaceuticals’ NDA for Omapro

ChemGenex Pharmaceuticals Limited announced today the U.S. Food and Drug Administration (FDA) has notified the company that the Oncologic Drugs Advisory Committee (ODAC) will conduct a public advisory meeting on 10 February 2010 to review the Company’s NDA for Omapro™ (omacetaxine mepesuccinate) for injection.

17 Dec 2009

Pharmaceutical News

Treprostinil drug reduces breathlessness in PAH patients, says study

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

BDI Pharma introduces SecuriVAX for online ordering of vaccines

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Antidepressants may play a key role in improving adolescents’ mental health

Duane Reade offers H1N1 immunization vaccines for New York residents

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Covidien signs definitive agreement to sell U.S. radiopharmacies to Triad Isotopes

Switching between A-rated anti-epileptic drug formulations does not increase seizure risk

EPA approves BASF's Aseptrol S10 - Tab for H1N1 sanitization operations

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Labopharm commences regulatory approval process in Europe for its twice-daily tramadol-acetaminophen

Prophylactic misuse of NSAIDs cause more harm than good

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

Three H1N1 influenza vaccination clinics scheduled to offer vaccines free of charge

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

FDA Advisory Committee votes against the approval of Tarceva

ODAC to review Cell Therapeutics' NDA for pixantrone

ODAC to conduct public advisory meeting to review ChemGenex Pharmaceuticals’ NDA for Omapro

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News